Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
Yahoo Finance · Jul 27, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) said the US Food and Drug Administration (FDA) has issued a "Study May Proceed" letter authorizing the company to begin its NDA-enabling Phase 2b registrational study of SkinJect in patients with Gorlin syndrome who develop multiple basal cell carcinomas. The...
Not investment advice. Cached headline, not a full reprint.